Lexapro (Escitalopram)
escitalopram 20 mg/mL oral liquid, 15 mL · ORAL · PBS code 10181W
RESTRICTEDWhat it costs
AU$24.15 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2014-12-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Major depressive disorders
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe generalised anxiety disorder (GAD)
The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
Patient must not have responded to non-pharmacological therapy; AND
Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe generalised anxiety disorder (GAD)
The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
Patient must not have responded to non-pharmacological therapy; AND
Patient must have been assessed by a psychiatrist.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe social anxiety disorder (social phobia, SAD)
The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
Patient must not have responded to non-pharmacological therapy; AND
Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe social anxiety disorder (social phobia, SAD)
The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
Patient must not have responded to non-pharmacological therapy; AND
Patient must have been assessed by a psychiatrist.
Sponsor: Lundbeck Australia Pty Ltd ABN 86 070 094 290
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.